Q2 FY2026 · ended Jun 30, 2026 · Revenue $209.30M, +335.1% YoY · Filed Aug 14, 2026
Vireo Growth Inc. (VREOF) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $209.3 million and a net loss of $100,000. Free cash flow was -$105.8 million. As of Jun 30, 2026 it held $115.8 million in cash and investments and $163.4 million in total debt.
Revenue
$209.30M
+335.1% vs year-ago quarter
Net income
$-100,000
+99.3% vs year-ago quarter
Operating cash flow
$2.40M
+150.0% vs year-ago quarter
Free cash flow
$-105.80M
-1144.7% vs year-ago quarter
EPS
$0.00
+100.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
—
Net cash
$-47.60M
Q2 FY2026
Operating margin
0.3%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VREOF (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Minneapolis, MN
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1771706
- Former names
- Goodness Growth Holdings, Inc. (until Jun 24, 2024); Vireo Health International, Inc. (until May 14, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $209.3M | $106.2M | $104.5M | $91.7M | $48.1M |
| Operating income | -$6.3M | $9.0M | -$1.8M | $808,956 | -$2.0M |
| Net income | -$100,000 | -$20.3M | -$20.4M | -$26.3M | -$14.9M |
| Diluted EPS | $0.00 | -$0.02 | -$0.02 | -$0.03 | -$0.80 |
| Operating cash flow | $2.4M | $11.9M | $18.7M | -$6.7M | -$4.8M |
| Free cash flow | -$105.8M | $1.1M | $8.8M | -$20.4M | -$8.5M |
| Total assets | $1.3B | $928.8M | $817.2M | $678.9M | $659.3M |
| Total liabilities | $831.2M | $634.7M | $509.8M | $432.6M | $390.8M |
| Stockholders' equity | $442.5M | $294.1M | $307.4M | $246.3M | $268.6M |
| Cash and investments | $115.8M | $129.4M | $109.2M | $104.2M | $113.2M |
| Total debt | $163.4M | — | — | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Agreement ended, New debt, Regulation FD disclosure
|
Oct 8, 2026 | Oct 2, 2026 |
| 8-K |
Current report
Acquisition or sale of assets, Unregistered share sale, Regulation FD disclosure
|
Aug 26, 2026 | Aug 21, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 18, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, New debt, Unregistered share sale, Regulation FD disclosure
|
Aug 13, 2026 | Aug 7, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
All 362 Vireo Growth Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.